# Lantheus

Source: https://onco.cc/companies/lantheus/  
OnCo record `lantheus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.

## Summary

Lantheus, based in Bedford, Massachusetts, and listed as LNTH, makes Pylarify, or piflufolastat F-18, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026. Its portfolio also includes Neuraceq for amyloid imaging, PNT2002, a 177Lu-PSMA-I&T therapy whose SPLASH phase 3 missed overall survival, and PNT2003, a generic 177Lu-DOTATATE, and OnCo also links it to iobenguane I-131 and samarium-153 lexidronam. It connects to prostate cancer, to PET tracer manufacturing and distribution and radionuclide generators, and to Evergreen Theragnostics. Whether an imaging leader can become a therapy company after SPLASH is the open question. Piflufolastat F-18 has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Progenics Pharmaceuticals, Inc.; Progenics; Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals
- HQ: Bedford, MA
- Type: radiopharma
- Website: https://www.lantheus.com
- Ticker: LNTH

## Sources

- Official website: https://www.lantheus.com

## Connected records

- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- drugs: [131I-MIBG (iobenguane I-131) therapy](https://onco.cc/drugs/i131-mibg/), [177Lu-PSMA-I&T](https://onco.cc/drugs/lu177-psma-it/), [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/), [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/)
- companies: [Evergreen Theragnostics](https://onco.cc/companies/evergreen-theragnostics/)
- trials: [64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer](https://onco.cc/trials/nct06298916/), [Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)](https://onco.cc/trials/nct07357519/), [SPLASH](https://onco.cc/trials/splash/), [Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer](https://onco.cc/trials/nct02981368/), [Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer](https://onco.cc/trials/nct03739684/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://onco.cc/technologies/cyclotron-isotope-production/), [PET tracer manufacturing and distribution](https://onco.cc/technologies/pet-tracer-manufacturing/), [Radionuclide generators and cold kits](https://onco.cc/technologies/radionuclide-generators-kits/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/)

---
JSON: https://onco.cc/api/v1/entities/lantheus.json